Bimekizumab

Drug Profile

Bimekizumab

Alternative Names: CDP-4940; UCB-4940

Latest Information Update: 23 Nov 2016

Price : $50

At a glance

  • Originator UCB
  • Class Antipsoriatics; Antirheumatics; Monoclonal antibodies
  • Mechanism of Action Interleukin-17 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Ankylosing spondylitis; Plaque psoriasis; Psoriatic arthritis; Rheumatoid arthritis; Ulcerative colitis
  • No development reported Psoriasis

Most Recent Events

  • 15 Nov 2016 Phase-II clinical trials in Plaque psoriasis in Germany (SC) (EudraCT2016-002368-15)
  • 08 Nov 2016 UCB Biopharma initiates an extension phase-II trial in Plaque psoriasis in Hungary (EudraCT2016-001892-57)
  • 05 Oct 2016 Phase-II clinical trials in Ulcerative colitis (Treatment-experienced) in Spain (SC and IV) (EudraCT2016-000420-26)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top